Compounders get version of PDUFA

Share this article:

The FDA is looking to get compounders to fill the inspection kitty. Regulatory Focus reports that the FDA has issued draft guidance that would allow the agency to collect fees from compounders, much as it collects PDUFA fees to fund drug reviews. RF notes that lawmakers approved the fee last fall, following a compounding crisis which killed more than 60 people, and during which the FDA said it lacked funding and authority to supervise compounders.

The approved legislation, known as the Drug Quality and Security Act, gave the FDA regulatory authority over what were deemed “outsourcing facilities.”

The fees described in today's RF pay for this supervision and include an annual $15,000 "establishment fee" ($5,000 for small businesses) and a $15,000 re-inspection fee. The guidance also includes an incentive: register as an oursourcing facility before October 1—the end of FY2014—and you don't have to pay that year's fees. These firms would still have to pay FY2015 fees.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.